Literature DB >> 10802504

Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome.

S Shenoy1, S Arnold, T Chatila.   

Abstract

We report a child who developed autoimmune lymphoproliferative syndrome (ALPS) secondary to a heterozygous dominant negative mutation in the death domain of the Fas receptor. Previously developmentally normal, he had symptoms of autism with rapid regression in developmental milestones coincident with the onset of lymphoproliferation and autoimmune hemolytic anemia. Low-dose steroid therapy induced early and complete remission in the ALPS phenotype. There was subjective improvement, followed by objective improvement in speech and developmental milestones. We propose that autism may be part of the autoimmune disease spectrum of ALPS in this child, and this case represents a novel manifestation and target organ involvement in this disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10802504     DOI: 10.1067/mpd.2000.105355

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  14 in total

Review 1.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 2.  Immune therapy in autism: historical experience and future directions with immunomodulatory therapy.

Authors:  Michael G Chez; Natalie Guido-Estrada
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 3.  Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment?

Authors:  Dominika Gładysz; Amanda Krzywdzińska; Kamil K Hozyasz
Journal:  Mol Neurobiol       Date:  2018-01-06       Impact factor: 5.590

Review 4.  Autoimmune lymphoproliferative syndrome: etiology, diagnosis, and management.

Authors:  Jutte van der Werff ten Bosch
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 5.  A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures.

Authors:  D A Rossignol; R E Frye
Journal:  Mol Psychiatry       Date:  2011-12-06       Impact factor: 15.992

Review 6.  A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel.

Authors:  Richard E Frye; Daniel Rossignol; Manuel F Casanova; Gregory L Brown; Victoria Martin; Stephen Edelson; Robert Coben; Jeffrey Lewine; John C Slattery; Chrystal Lau; Paul Hardy; S Hossein Fatemi; Timothy D Folsom; Derrick Macfabe; James B Adams
Journal:  Front Public Health       Date:  2013-09-13

Review 7.  Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism.

Authors:  Daniel A Rossignol; Richard E Frye
Journal:  Front Physiol       Date:  2014-04-22       Impact factor: 4.566

8.  Safety and Observations from a Placebo-Controlled, Crossover Study to Assess Use of Autologous Umbilical Cord Blood Stem Cells to Improve Symptoms in Children with Autism.

Authors:  Michael Chez; Christopher Lepage; Carol Parise; Ashley Dang-Chu; Andrea Hankins; Michael Carroll
Journal:  Stem Cells Transl Med       Date:  2018-02-06       Impact factor: 6.940

9.  Corticosteroid therapy in regressive autism: Preliminary findings from a retrospective study.

Authors:  Sailaja Golla; John A Sweeney
Journal:  BMC Med       Date:  2014-05-15       Impact factor: 8.775

10.  Corticosteroid therapy in regressive autism: a retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior.

Authors:  Frank H Duffy; Aditi Shankardass; Gloria B McAnulty; Yaman Z Eksioglu; David Coulter; Alexander Rotenberg; Heidelise Als
Journal:  BMC Neurol       Date:  2014-05-15       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.